Lantern Pharma to Debut Public Demonstration of withZeta.ai, Showcasing AI Co-Scientist Platform for Rare Cancer Breakthroughs

Lantern Pharma (Nasdaq: LTRN) will host its first fully public, live demonstration of withZeta.ai on April 30, offering an unfiltered look at its multi-agent AI platform accelerating rare cancer drug discovery in real time. With the AI-driven drug discovery market projected to exceed $15B by 2030, the platform’s scalable subscription model and ability to compress months of research into minutes position it as a powerful new revenue driver for Lantern Pharma.

Recent News

Off The Hook YS Inc. (NYSE-A: OTH) is a vertically integrated, AI-powered marine marketplace focused on buying, selling, and financing pre-owned boats across the United States. Its core platform, anchored by WeBuyBoats.com and a growing national broker network, operates as a liquidity engine in the fragmented $10 billion used boat market, a segment where the majority of transactions still happen without the speed, transparency, or data infrastructure that modern commerce demands.

First Phosphate Corp. (OTCQX-ADR: FPHOY | OTCQX: FRSPF | CSE: PHOS) is a Quebec-based critical minerals developer building a vertically integrated supply chain for lithium iron phosphate (LFP) battery materials in North America. The company's flagship Bégin-Lamarche Property in the Saguenay–Lac-Saint-Jean region of Quebec is a rare, large-scale igneous phosphate deposit being advanced toward a full feasibility study. On January 7, 2026, Mark Reichman, Managing Director of Equity Research at Noble Capital Markets, maintained an Outperform rating and a price target of US$1.55 per share on First Phosphate Corp., representing implied upside of approximately 104% from the share price of $0.76.

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company using artificial intelligence to discover and develop precision oncology therapies. Its lead asset, LP-300, is currently in a Phase 2 clinical trial targeting never-smoker non-small cell lung cancer (NSCLC), a patient population with no FDA-approved therapy specifically designed for them. On March 31, 2026, Lake Street Capital Markets reaffirmed a Buy rating and $25 price target on Lantern Pharma (NASDAQ: LTRN), implying upside of more than 1,400% from current levels. The near-term catalyst is a Type C meeting with the FDA scheduled for May 14, 2026.

OBOOK Holdings, Inc. (Nasdaq: OWLS) is rapidly positioning OwlPay as a next-generation cross-border payments backbone, leveraging stablecoin rails to deliver near-instant settlement at dramatically lower costs—addressing a global market projected to reach $320 trillion by 2032. With expanding regulatory licenses, major partnerships like Visa Direct, and projected revenue growth accelerating toward $100M+, the company is converting its compliance moat into high-margin, recurring infrastructure revenue.

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases and advanced liver disease. Its lead asset, bezisterim (NE3107), is an orally available small molecule targeting neuroinflammation and insulin resistance, which are two of the principal biological drivers behind Parkinson's disease (PD), Alzheimer's disease (AD), and Long COVID. The company received a buy rating and $6 price target from Brookline Capital Markets in March 2025.

Upcoming Events

Archived Events

Quote of the Week

Order “Small Stocks, Big Money™” Today!

Dave Gentry's new book, Small Stocks, Big Money: Interviews With Microcap Superstars, is now available for pre-order. Published by Wiley Finance, this first-hand perspective and insider information on the fast world of microcap investing is now available for purchase.

You are receiving this email because you have subscribed to receive updates from us.
Should you wish to cancel your subscription, please click here to manage preferences.